2 results
Approved WMOCompleted
Primary objectives: Dose-expansion:To evaluate the antitumor activity of MEDI0680 in combination with durvalumab versus nivolumab monotherapy in immunotherapy-naïve subjects with advanced or metastatic ccRCC as based on investigator assessed…
Approved WMOPending
Primary objective: To measure AF burden at population level.Secondary objective: Associate the AF burden with risk profiles in the general population.